Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
Medtronic
Baxter
Harvard Business School

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR RAMIPRIL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Ramipril

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005928 ↗ Effects of Angiotensin-Converting Enzyme Inhibitor (Ramipril) Therapy on Blood Vessel Inflammation Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 2000-06-01 This study will determine the effects of angiotensin-converting enzyme (ACE) inhibitor (trade name Ramipril) therapy on inflammation and stiffness of artery walls. These are two risk factors for developing atherosclerosis-deposits of fatty substances called plaques that can block the blood vessel, causing a heart attack or stroke. Studies of patients with coronary artery disease suggest that ACE inhibitor therapy reduces the risk of heart attack and heart failure. This study will examine the effects of this treatment on the artery walls and on levels of substances in the blood that indicate blood vessel inflammation. Patients between 40 and 75 years old with coronary artery disease caused by atherosclerosis may be eligible for this study. Candidates will be screened with a medical history, cardiovascular (heart and blood vessel) examination, electrocardiogram and blood tests. Those enrolled will be randomly assigned to take either an ACE inhibitor pill or a placebo (look-alike pill with no medicine) once a day for 3 months. No pills will be taken for the next month, and then participants will take the alternate pill for the next 3 months. That is, those who took ACE inhibitor for the first 3-month period will take placebo for the second 3-month period and vice versa. Blood pressures will be taken at the NIH Clinical Center or by the patient's physician at the end of the first and second weeks of the study. At the end of 3 weeks, patients will return to the Clinical Center for a blood draw of 6 cc (1/2 teaspoon) to assess kidney function. In addition, at the end of each 3-month study period, patients will undergo the following procedures at the Clinical Center: 1. Fasting blood draw of 60 cc (2 ounces) to measure electrolytes (e.g., sodium and potassium) and blood markers for inflammation 2. Ultrasound (use of sound waves to create pictures) study of the carotid arteries (arteries in the neck leading to the brain)-An ultrasound probe is applied gently on the neck, and ultrasound pictures of the right and left carotid arteries are recorded on tape. Heart activity and blood pressure are monitored during the procedure with an electrocardiogram and blood pressure cuff. 3. Magnetic resonance imaging (MRI) of the carotid arteries-The patient lies on a table in a narrow cylinder (the MRI machine) containing a magnetic field. A flexible padded sensor called a MRI coil is placed over the neck area. Earplugs are placed in the ear to muffle the loud thumping sounds the machine makes when the magnetic fields are switched. During the second half of the exam, a contrast agent (gadolinium) is injected through an intravenous catheter (flexible tube placed in a vein) to brighten the images. The heart is monitored during the procedure with an electrocardiogram.
NCT00044265 ↗ Treatment of Pediatric Hypertension With Altace Trial Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2002-07-01 Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
NCT00044265 ↗ Treatment of Pediatric Hypertension With Altace Trial Completed Pfizer Phase 4 2002-07-01 Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
NCT00054938 ↗ Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) Completed National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Phase 2 2003-03-01 The purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or SLE). The study will evaluate the effectiveness of medication and a phone-based education program in controlling four risk factors for heart disease: smoking, obesity, high blood pressure, and inactivity. The study will also test the safety of commonly used heart medications in people with lupus.
NCT00054938 ↗ Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) Completed Brigham and Women's Hospital Phase 2 2003-03-01 The purpose of this study is to find the best way to prevent heart disease and stroke in people with lupus (systemic lupus erythematosis, or SLE). The study will evaluate the effectiveness of medication and a phone-based education program in controlling four risk factors for heart disease: smoking, obesity, high blood pressure, and inactivity. The study will also test the safety of commonly used heart medications in people with lupus.
NCT00095290 ↗ Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria Completed Sanofi Phase 4 2004-09-01 Albumin in the urine is usually a signal that you might be at risk of cardiovascular complications. The purpose of this study is to determine if the albumin in your urine can be decreased by the treatment regimen that consists of irbesartan taken at the same time with ramipril.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ramipril

Condition Name

Condition Name for Ramipril
Intervention Trials
Hypertension 47
Healthy 17
Diabetic Nephropathy 8
Diabetes 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ramipril
Intervention Trials
Hypertension 57
Kidney Diseases 19
Diabetes Mellitus 17
Renal Insufficiency, Chronic 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ramipril

Trials by Country

Trials by Country for Ramipril
Location Trials
United States 302
Canada 53
Italy 46
Spain 32
Germany 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ramipril
Location Trials
Texas 18
California 17
New York 13
Illinois 13
Ohio 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ramipril

Clinical Trial Phase

Clinical Trial Phase for Ramipril
Clinical Trial Phase Trials
Phase 4 59
Phase 3 40
Phase 2/Phase 3 7
[disabled in preview] 56
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ramipril
Clinical Trial Phase Trials
Completed 115
Terminated 15
Unknown status 14
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ramipril

Sponsor Name

Sponsor Name for Ramipril
Sponsor Trials
Boehringer Ingelheim 12
Sanofi 11
Novartis Pharmaceuticals 9
[disabled in preview] 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ramipril
Sponsor Trials
Other 154
Industry 93
NIH 12
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Moodys
Baxter
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.